Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: A double-blind, randomised controlled trial

The Lancet Respiratory Medicine

Volumn 3, Issue 7, 2015, Pages 524-533

  Moss, Richard B ^a   Flume, Patrick A ^b   Elborn, J Stuart ^c   Cooke, Jon ^d   Rowe, Steven M ^e   McColley, Susanna A ^f   Rubenstein, Ronald C ^g   Higgins, Mark ^d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d VERTEX PHARMACEUTICALS   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; PLACEBO; AMINOPHENOL DERIVATIVE; CFTR PROTEIN, HUMAN; CHLORIDE CHANNEL; QUINOLONE DERIVATIVE; RESPIRATORY TRACT AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; BODY MASS; CELLULITIS; CHILD; CONSTIPATION; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; CYSTIC FIBROSIS QUESTIONNAIRE REVISED; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; GENE MUTATION; HEADACHE; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE OBSTRUCTION; OPEN STUDY; OROPHARYNX PAIN; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE ASSESSMENT; SIDE EFFECT; SPUTUM; SWEAT; URTICARIA; WHEEZING; AGED; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; MIDDLE AGED; MUTATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMINOPHENOLS; CHILD; CHLORIDE CHANNELS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MUTATION; QUINOLONES; RESPIRATORY SYSTEM AGENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84943138352     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00201-5     Document Type: Article

References (39)

1. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989, 245:1059-1065.
2. Boucher RC Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 2007, 58:157-170.
3. Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013, 187:1219-1225.
4. Cystic Fibrosis Foundation patient registry 2013 annual data report 2014, Cystic Fibrosis Foundation, Bethesda, MD.
5. Sheppard DN, Rich DP, Ostedgaard LS, Gregory RJ, Smith AE, Welsh MJ Mutations in CFTR associated with mild-disease-form Cl- channels with altered pore properties. Nature 1993, 362:160-164.
6. Kiesewetter S, Macek M, Davis C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet 1993, 5:274-278.
7. Tabaripour R, Niaki HA, Douki MR, Bazzaz JT, Larijani B, Yaghmaei P Poly thymidine polymorphism and cystic fibrosis in a non-Caucasian population. Dis Markers 2012, 32:241-246.
8. Bobadilla JL, Macek M, Fine JP, Farrell PM Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 2002, 19:575-606.
9. Chavez-Saldana M, Yokoyama E, Lezana JL, et al. CFTR allelic heterogeneity in Mexican patients with cystic fibrosis: implications for molecular screening. Rev Invest Clin 2010, 62:546-552.
10. Claustres M, Guittard C, Bozon D, et al. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. Hum Mutat 2000, 16:143-156.
11. Alonso MJ, Heine-Suner D, Calvo M, et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. Ann Hum Genet 2007, 71:194-201.
12. Estivill X, Bancells C, Ramos C Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. Hum Mutat 1997, 10:135-154.
13. Lucotte G, Hazout S Geographic and ethnic distributions of the more frequent cystic fibrosis mutations in Europe show that a founder effect is apparent for several mutant alleles. Hum Biol 1995, 67:562-576.
14. Thauvin-Robinet C, Munck A, Huet F, et al. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening. J Med Genet 2009, 46:752-758.
15. Comer DM, Ennis M, McDowell C, et al. Clinical phenotype of cystic fibrosis patients with the G551D mutation. QJM 2009, 102:793-798.
16. McKone EF, Emerson SS, Edwards KL, Aitken ML Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003, 361:1671-1676.
17. Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012, 11:237-245.
18. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009, 106:18825-18830.
19. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011, 365:1663-1672.
20. De Boeck K, Munck A, Walker S, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 2014, 13:674-680.
21. Rosenstein BJ, Cutting GR The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998, 132:589-595.
22. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995, 152:1107-1136. American Thoracic Society.
23. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005, 128:2347-2354.
24. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009, 135:1610-1618.
25. Van Goor F, Yu H, Burton B, Hoffman BJ Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros 2014, 13:29-36.
26. Carter S, Kelly S, Caples E, et al. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T. J Cyst Fibros 2015, published online Feb 16. 10.1016/j.jcf.2015.01.010.
27. Char JE, Wolfe MH, Cho HJ, et al. A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor. PLoS One 2014, 9:e88564.
28. Massie RJ, Poplawski N, Wilcken B, Goldblatt J, Byrnes C, Robertson C Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. Eur Respir J 2001, 17:1195-1200.
29. Shteinberg M, Downey D, Beattie D, et al. Clinical characteristics of CF patients with R117H mutation and different polythymidine tract variants [abstract]. Presented at the 28th Annual North American Cystic Fibrosis Conference, Atlanta, GA, October 9-11, 2014.
30. Sheppard DN, Welsh MJ Inhibition of the cystic fibrosis transmembrane conductance regulator by ATP-sensitive K+ channel regulators. Ann NY Acad Sci 1993, 707:275-284.
31. The Cystic Fibrosis Genotype-Phenotype Consortium. N Engl J Med 1993, 329:1308-1313. Correlation between genotype and phenotype in patients with cystic fibrosis.
32. Morral N, Dork T, Llevadot R, et al. Haplotype analysis of 94 cystic fibrosis mutations with seven polymorphic CFTR DNA markers. Hum Mutat 1996, 8:149-159.
33. Morral N, Llevadot R, Casals T, et al. Independent origins of cystic fibrosis mutations R334W, R347P, R1162X, and 3849 + 10kbC->T provide evidence of mutation recurrence in the CFTR gene. Am J Hum Genet 1994, 55:890-898.
34. Rave-Harel N, Kerem E, Nissim-Rafinia M, et al. The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. Am J Hum Genet 1997, 60:87-94.
35. Peckham D, Conway SP, Morton A, Jones A, Webb K Delayed diagnosis of cystic fibrosis associated with R117H on a background of 7T polythymidine tract at intron 8. J Cyst Fibros 2006, 5:63-65.
36. Borowitz D, Parad RB, Sharp JK, et al. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr 2009, 155:S106-S116.
37. Groman JD, Hefferon TW, Casals T, et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 2004, 74:176-179.
38. Nissim-Rafinia M, Chiba-Falek O, Sharon G, Boss A, Kerem B Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. Hum Mol Genet 2000, 9:1771-1778.
39. Cui G, Freeman CS, Knotts T, Prince CZ, Kuang C, McCarty NA Two salt bridges differentially contribute to the maintenance of cystic fibrosis transmembrane conductance regulator (CFTR) channel function. J Biol Chem 2013, 288:20758-20767.